Who is sponsoring AUSTRAL?

AUSTRAL is sponsored by Mario Negri Institute for Pharmacological Research.

What condition does AUSTRAL study?

AUSTRAL studies Non Small Cell Lung Cancer NSCLC.

What drugs are being tested in AUSTRAL?

Interventions: Durvalumab (MEDI4736), Ceralasertib, radiotherapy.

What is the status of AUSTRAL?

AUSTRAL is currently RECRUITING.

Last reviewed 2025-12-10 · How we verify

AUSTRAL Trial: An Open-Label, Multicenter, Phase II Study Of Radiotherapy Followed By Durvalumab (MEDI4736) And Ceralasertib (AZD6738) In Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

NCT06680050 Phase 2 RECRUITING

Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (\<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses +/- oligometastases after PACIFIC or PACIFIC-like (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab) regimens.

Details

Lead sponsor	Mario Negri Institute for Pharmacological Research
Phase	Phase 2
Status	RECRUITING
Enrolment	21
Start date	2025-08-07
Completion	2029-01

Conditions

Non Small Cell Lung Cancer NSCLC

Interventions

Durvalumab (MEDI4736)
Ceralasertib
radiotherapy

Primary outcomes

Safety and tolerability, in terms of number of grade 3 or higher adverse events judged as at least possibly related to study treatment regimen — within 6 months from the start of study treatment
PFS — 12 months
PFS is defined as the time from the date of enrolment until the date of first disease progression or death to any cause, whichever comes first.

Countries

Italy, Switzerland